Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Glycemic control and blood product quality of Canadian blood donors with diabetes.

Transfusion·2026

Same author

Manufacturing stresses do not differentially impact red blood cells from donors with diabetes.

Vox sanguinis·2025

Same author

Hemocompatibility of cyclodextrin-coated magnetic nanoparticles under uremic conditions.

Carbohydrate polymers·2025

Same author

Investigation on the Influence of Protein Corona and Platelet Adhesion on Storage Bag Surface on the Platelet Storage Lesion.

Advanced healthcare materials·2025

Same author

Characterization and Hemocompatibility of α, β, and γ Cyclodextrin-Modified Magnetic Nano-Adsorbents.

International journal of molecular sciences·2024

Same author

Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices.

Blood·2024

Search research articles

Related Experiment Video

Updated: Aug 18, 2025

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Novel platelet products including cold-stored platelets.

Dana V Devine¹

¹Canadian Blood Services and the University of British Columbia Centre for Blood Research, Vancouver, Canada.

Hematology. American Society of Hematology. Education Program

|December 9, 2022

Summary

New platelet products like pathogen-inactivated, cold-stored, and cryoplatelets are nearing clinical use. This review examines their limitations and knowledge gaps for effective patient treatment.

More Related Videos

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Related Experiment Videos

Last Updated: Aug 18, 2025

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Area of Science:

Transfusion Medicine
Hematology
Blood Product Innovation

Background:

Traditional platelet transfusions face limitations in storage and pathogen safety.
Emerging platelet products aim to address these challenges, expanding transfusion options.
Understanding the clinical utility of these novel products is crucial for transfusion services.

Approach:

This article provides a comprehensive review of three advanced platelet preparations: pathogen-inactivated platelets, cold-stored platelets, and cryoplatelets.
It analyzes the current limitations and potential drawbacks associated with each product.
The review identifies critical gaps in scientific understanding regarding their optimal use in patient care.

Key Points:

Pathogen inactivation, cold storage, and cryopreservation represent significant advancements in platelet technology.
Each method presents unique technical and clinical challenges that require further investigation.
Limited clinical data exists on the efficacy and safety of these products in diverse patient populations.

Conclusions:

Pathogen-inactivated platelets, cold-stored platelets, and cryoplatelets are poised for integration into clinical practice.
Further research is essential to fully elucidate their therapeutic roles and optimize their application.
Addressing the identified knowledge gaps will facilitate the safe and effective implementation of these innovative transfusion therapies.